Payment overview · 2025
General Payments
$910.31
42 reported records · 16 companies
Healthcare provider profile · identity verified
Benson Albert Grigsby, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RUSTON, LA · NPI 1487687513
Verified facts
What the public records show
CMS Open Payments records show Benson Albert Grigsby, M.D. received $910.31 in general payments during 2025 across 42 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Ozempic, Rexulti, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.48 | 15.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $128.11 | 14.1% | 6 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $83.51 | 9.2% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.92 | 9.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.43 | 8.0% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.09 | 6.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.01 | 6.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $43.78 | 4.8% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $43.09 | 4.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.72 | 4.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.74 | 4.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.57 | 4.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.77 | 3.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.68 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.28 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.13 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $910.31 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.05 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $84.05 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $83.51 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.92 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $70.49 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $62.09 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $44.06 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $44.06 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $44.06 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $43.78 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $43.09 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.65 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.74 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.74 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $11.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 23 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 608 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 564 | 140 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 301 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 74 |
| Lisinopril | Lisinopril | 276 | 76 |
| Gabapentin | Gabapentin | 262 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 242 | 44 |
| Alprazolam | Alprazolam | 240 | 35 |
| Metformin Hcl | Metformin Hcl | 240 | 57 |
| Omeprazole | Omeprazole | 236 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 57 |
| Potassium Chloride | Potassium Chloride | 202 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 39 |
| Simvastatin | Simvastatin | 166 | 45 |
| Sertraline Hcl | Sertraline Hcl | 165 | 34 |
| Tramadol Hcl | Tramadol Hcl | 162 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 37 |
| Furosemide | Furosemide | 150 | 41 |
| Valsartan | Valsartan | 150 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 43 |
| Eliquis | Apixaban | 142 | 23 |
| Trazodone Hcl | Trazodone Hcl | 129 | 27 |
| Ezetimibe | Ezetimibe | 126 | 28 |
| Losartan Potassium | Losartan Potassium | 121 | 34 |
| Meloxicam | Meloxicam | 120 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 115 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 23 |
| Montelukast Sodium | Montelukast Sodium | 110 | 23 |
| Mounjaro | Tirzepatide | 110 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 16 |
| Clonazepam | Clonazepam | 91 | 17 |
| Synthroid | Levothyroxine Sodium | 91 | 19 |
| Finasteride | Finasteride | 90 | 20 |
| Lorazepam | Lorazepam | 87 | 21 |
| Donepezil Hcl | Donepezil Hcl | 84 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 22 |
| Estradiol | Estradiol | 76 | 18 |
| Nifedipine Er | Nifedipine | 76 | 19 |
| Trintellix | Vortioxetine Hydrobromide | 75 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 16 |
| Jardiance | Empagliflozin | 64 | 20 |
| Memantine Hcl | Memantine Hcl | 64 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 20 |
| Carvedilol | Carvedilol | 60 | 14 |
| Farxiga | Dapagliflozin Propanediol | 60 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 42 |
| Allopurinol | Allopurinol | 55 | 15 |
| Fluconazole | Fluconazole | 55 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 54 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Atenolol | Atenolol | 50 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Mupirocin | Mupirocin | 46 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 13 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Prednisone | Prednisone | 44 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 30 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Carisoprodol | Carisoprodol | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 12 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Acyclovir | Acyclovir | 37 | 16 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 18 |
| Cefuroxime | Cefuroxime Axetil | 31 | 26 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 29 |
| Colestipol Hcl | Colestipol Hcl | 30 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 23 |
| Famotidine | Famotidine | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Indomethacin | Indomethacin | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 20 |
| Naproxen | Naproxen | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Nystop | Nystatin | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $910.31 · 42 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FARXIGA, GEMTESA, Kerendia, LINZESS, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, REPATHA, REXULTI, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error